Clinical Trials: Find a Clinical Trial

At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.

The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.

Showing 121 - 140 of 505 trials
Title Investigatorsort icon Disease(s)
A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
[Protocol 12-113]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK-Positive Lung Cancers
[Protocol 12-015]
Riely, Gregory
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase II Study of Temozolomide Alone and with Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
[Protocol 13-194]
Reidy-Lagunes, Diane
  • Hepatobiliary
    • Pancreatic Cancer
  • Upper Gastrointestinal
    • Neuroendocrine
    • Pancreatic Cancer
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana
  • Prostate Cancer
    • Localized Disease
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana
  • Prostate Cancer
    • Rising PSA After Primary Therapy
A Phase II Study of AUY922 in Patients with Myelofibrosis
Newly Diagnosed & Relapsed/Refractory
[Protocol 12-076]
Rampal, Raajit
  • Hematology
    • Hematologic Disorders
    • Hematologic Malignancies
  • Leukemia
    • Myeloproliferative Neoplasm
  • Rare Blood Disorders
Development and Validation of a New Patient-Reported Outcome Instrument on the Impact of Altered Facial Appearance Following Oncologic Head and Neck Resection and Reconstruction
[Protocol 07-098]
Pusic, Andrea
  • Head & Neck Cancer
  • Survivorship
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea
  • Breast Cancer
  • Survivorship
Microvascular Reconstruction for Advanced-Stage Head and Neck Cancer Patients: A Prospective Analysis of Quality of Life and Symptom Relief
[Protocol 07-150]
Pusic, Andrea
  • Head & Neck Cancer
  • Quality of Life
A Study Analyzing Patients Treated for Wiskott-Aldrich Syndrome Since 1990
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-066]
Prockop, Susan
  • Hematology
    • Hematologic Disorders
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD
[Protocol 09-072]
Prockop, Susan
  • Blood and Marrow Transplantation
    • Transplantation
A Phase III Study of MEK162 versus Dacarbazine in Patients with Inoperable or Metastatic Melanomas with NRAS Q61 Mutations: The NEMO Trial
[Protocol 13-083]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus LGX818 in Patients with BRAF-Mutant Melanoma
[Protocol 13-097]
Postow, Michael
  • Melanoma
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael
  • Melanoma
Expanded Access to MK-3475 for Patients with Metastatic Melanoma with Few to No Treatment Options
[Protocol 14-093]
Postow, Michael
  • Melanoma
A Phase I Study of the NY-ESO-1 Vaccine plus Ipilimumab in Patients with Inoperable or Metastatic Melanoma
[Protocol 12-253]
Postow, Michael
  • Melanoma
A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma
[Protocol 13-172]
Postow, Michael
  • Melanoma
    • Melanoma of the Eye